Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review
- PMID: 24883145
- PMCID: PMC4039091
- DOI: 10.14740/jocmr1858w
Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review
Abstract
The objective of the paper is to review the literature and provide recommendations for use of aminoglycoside antibiotics in critically ill obese patients. Literature search in PubMed for all articles on the use of aminoglycosides in critically ill obese patients was conducted, and all articles related to pharmacokinetics in obesity were reviewed. Bibliographies of all searched manuscripts were also reviewed in an attempt to find additional references. Although aminoglycoside pharmacokinetics have been described in detail, data on aminoglycoside use and appropriate dose modification in critically ill obese patients are very limited. Knowledge on aminoglycoside pharmacokinetics and use in critically ill obese patients is incomplete. Pathophysiologic changes in obesity can result in sub- or supra-therapeutic aminoglycoside plasma concentrations, especially in the presence of sepsis. Rigorous clinical studies are needed to establish aminoglycoside dosing guidelines in critically ill obese patients with sepsis.
Keywords: Amikacin; Aminoglycoside; Critical illness; Gentamicin; Obesity; Pharmacokinetics; Sepsis; Tobramycin.
Similar articles
-
Aminoglycoside Dosing and Volume of Distribution in Critically Ill Surgery Patients.Surg Infect (Larchmt). 2020 Dec;21(10):859-864. doi: 10.1089/sur.2020.012. Epub 2020 Apr 17. Surg Infect (Larchmt). 2020. PMID: 32302517
-
Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?Antibiotics (Basel). 2021 Apr 29;10(5):507. doi: 10.3390/antibiotics10050507. Antibiotics (Basel). 2021. PMID: 33946905 Free PMC article. Review.
-
The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients.Surg Infect (Larchmt). 2009 Dec;10(6):563-70. doi: 10.1089/sur.2007.080. Surg Infect (Larchmt). 2009. PMID: 20035611 Review.
-
Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.Expert Rev Anti Infect Ther. 2017 Jun;15(6):519-526. doi: 10.1080/14787210.2017.1316193. Epub 2017 Apr 17. Expert Rev Anti Infect Ther. 2017. PMID: 28375030 Review.
-
Experience with a once-daily dosing program of aminoglycosides in critically ill patients.Intensive Care Med. 2002 Jul;28(7):936-42. doi: 10.1007/s00134-002-1313-7. Epub 2002 May 30. Intensive Care Med. 2002. PMID: 12122533
Cited by
-
The Crashing Obese Patient.West J Emerg Med. 2019 Mar;20(2):323-330. doi: 10.5811/westjem.2018.12.41085. Epub 2019 Feb 6. West J Emerg Med. 2019. PMID: 30881553 Free PMC article. Review.
-
Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients.Antimicrob Agents Chemother. 2019 Oct 22;63(11):e00993-19. doi: 10.1128/AAC.00993-19. Print 2019 Nov. Antimicrob Agents Chemother. 2019. PMID: 31481443 Free PMC article.
-
Is fat-free mass-based gentamicin dosing regimen preferable than whole-body weight in neonates?Pediatr Investig. 2023 Jun 8;7(2):86-94. doi: 10.1002/ped4.12386. eCollection 2023 Jun. Pediatr Investig. 2023. PMID: 37324598 Free PMC article.
-
Individual pharmacokinetic parameter estimation of gentamicin in an obese hemodialysis patient using non-linear mixed effect model.Transl Clin Pharmacol. 2024 Sep;32(3):150-158. doi: 10.12793/tcp.2024.32.e14. Epub 2024 Sep 25. Transl Clin Pharmacol. 2024. PMID: 39386271 Free PMC article.
-
Updated antimicrobial dosing recommendations for obese patients.Antimicrob Agents Chemother. 2024 May 2;68(5):e0171923. doi: 10.1128/aac.01719-23. Epub 2024 Mar 25. Antimicrob Agents Chemother. 2024. PMID: 38526051 Free PMC article.
References
-
- Blouin RA, Mann HJ, Griffen WO, Jr., Bauer LA, Record KE. Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther. 1979;26(4):508–512. - PubMed
-
- Bauer LA, Blouin RA, Griffen WO, Jr., Record KE, Bell RM. Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm. 1980;37(4):519–522. - PubMed
-
- Korsager S. Administration o gentamicin to obese patients. Int J Clin Pharmacol Ther Toxicol. 1980;18(12):549–553. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources